FIND A DERM    

MIRVASO

Rosacea Redness

Savings

To get your MIRVASO Gel Patient Savings Card, click OK below. You will be redirected to an external website that is independently operated and not managed by Galderma Laboratories, L.P. Galderma assumes no responsibility for the site you are about to visit. If you do not wish to leave Mirvaso.com, click CANCEL. Otherwise, click OK to continue.

CANCEL
OK
MIRVASO® (brimonidine) topical gel, 0.33%* is the first & only FDA-approved treatment developed and indicated for persistent facial redness of rosacea
/Content/images/home-woman-1.jpg

Not an actual patient. Individual results may vary. Results are simulated to show a 2-grade improvement of the facial redness of rosacea. At hour 12 on day 29, 22% of subjects using MIRVASO Gel experienced a 2-grade improvement of facial redness compared with 9% of people using the vehicle gel.

MIRVASO® (brimonidine) topical gel, 0.33%* is the first and only FDA-approved treatment developed and indicated for persistent (nontransient) facial redness of rosacea. Facial redness is a common symptom of rosacea, a skin condition that affects an estimated 16 million Americans. SEE REAL RESULTS
savings card
Break Up With Your Make Up Contest

Important Safety Information
Indication:  MIRVASO® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions:  MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

Phase 3 clinical studies of 553 subjects aged 18 and older. Half of the study participants used MIRVASO Gel and the other half used a gel with no active ingredient (vehicle gel) for 29 days. Subjects and researchers were asked to grade the improvement they saw at 30 minutes and at hours 3, 6, 9, and 12 following application.

Certain limitations may apply. Click here for program details.

All trademarks are the property of their respective owners.

PROGRAM DETAILS:

The Galderma® CareConnect Program is brought to you by Galderma Laboratories, L.P. The Patient Savings Card provides savings on out‑of‑pocket expenses for up to a 30‑day supply of included Galderma products, as described below. If you have valid prescriptions for more than one Galderma product, the copay expense and savings apply to each product. You may use the Patient Savings Card once every 30 days, depending on when you last received a 30‑day supply of each Galderma product. Use of the Patient Savings Card does not obligate you to use or to continue using any Galderma product. You may use the Patient Savings Card at any participating pharmacy located in the United States.

The Galderma CareConnect Program Patient Savings Card may not be combined with any savings, discount, free trial, or other similar offer for the same prescription. The Patient Savings Card is not transferable and is void if reproduced. The Patient Savings Card is not health insurance. Limit one (1) Patient Savings Card per patient. The Galderma CareConnect Program Patient Savings Card has no cash value and will not be accepted outside of participating pharmacies in the United States. Please visit Galderma’s website for our privacy practices. Galderma reserves the right to revoke or amend this offer without notice at any time and to deny payment for noncompliance with the terms of this offer. This offer expires December 31, 2016, unless this offer is earlier terminated by Galderma.

Use of this Patient Savings Card is subject to applicable state and federal law, and is void where prohibited by law, rule or regulation. In the event an AB rated generic equivalent product becomes available for one of the Galderma products covered by this Patient Savings Card, this offer will become void in Massachusetts with respect to that Galderma product.

You are encouraged to report negative side effects of prescription drugs to the FDA.

By using the Galderma CareConnect Program Patient Savings Card, you acknowledge that you currently meet the following eligibility criteria:

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

1 of 4
Yes No
2 of 4
Yes No
3 of 4
Yes No
4 of 4
Yes No


You answered yes to questions.

Your facial redness could be related to rosacea.
To know for sure, visit your doctor and discuss your symptoms.


Your answers don't provide enough information to tell you if you could have the
facial redness of rosacea. Talk to your doctor about your symptoms.

Find a Dermatologist:
Next


Important Safety Information
Indication:  MIRVASO® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions:  MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Continue to mirvaso.com

MIRVASO Study Description

MIRVASO was tested in 2 medical studies with 553 people aged 18 and older. Half of study participants used MIRVASO and the other half used a gel with no active ingredient for 29 days. Patients and researchers were asked to grade the improvement they saw at hours 3, 6, 9, and 12. On Day 29 of the trials, 2-grade improvement was observed with MIRVASO versus inactive gel at Hour 3 (28% vs 10%), at Hour 6 (28% vs 9%), at Hour 9 (22% vs 10%), and at Hour 12 (22% vs 9%). At 30 minutes on Day 1, 28% of patients using MIRVASO experienced 1-grade improvement of facial redness versus 6% for people using the inactive gel. Individual results with MIRVASO may vary.